1st and only HAE treatment indicated for use in pediatrics. Learn more ►
Patient and professional support–on demand.

With help from Berinert Expert Network (B.E.N.®), you save administration time and make access to treatment easy for you and your patients.

Berinert Availability/Reimbursement and Product Codes CSL Behring is dedicated to making Berinert available to patients and healthcare professionals when and where it is needed. Berinert is available via a range of national and regional specialty pharmacies and distributors.

If you need contact information for these organizations, please call BEN toll-free 24/7 at 1-877-BEN-4HAE (1-877-236-4423).

Ready to Order Berinert?

Print a copy of this coding guide and keep it handy when diagnosing and ordering Berinert or when filing insurance claims on behalf of your patients.

HCPCS Code/Description17 (Healthcare Common Procedural Coding System)

J0597 Injection, C1 Esterase Inhibitor (Human), Berinert, 10 units

ICD-10-CM Diagnosis Code18 (Identifies the medical condition of the patient)

Primary Code: D84.1 C1 esterase inhibitor [C1-INH] deficiency
CPT® Codes19: 96374 Intravenous push, single, or initial substance/drug
96376 Each additional sequential intravenous push of the same substance/drug provided in a facility (list separately in addition to code for primary procedure)

Berinert NDC Numbers

Product kit NDC number from package insert NDC number to use on claim forms
Carton contains:
  • 500 U vial of Berinert
  • 10 mL vial of diluent (sterile water) for injection
  • Mix2Vial™ filter transfer set
  • Alcohol swab
  • Berinert package insert
63833-825-02 63833-0825-02

This resource provides information from a complex and evolving medical coding system. The treating physician is solely responsible for diagnosis coding and determination of the appropriate ICD-10-CM codes that describe the patient's conditions and are supported by the medical record. All codes listed in this guide are for informational purposes and are not an exhaustive list. The CPT, HCPCS, and ICD-10-CM codes are provided based on AMA or CMS guidelines. The billing party is solely responsible for coding of service (eg, CPT coding). Because government and other third-party payor coding requirements change periodically, please verify current coding requirements directly with the payor being billed.

Save on Co-Pays: The Berinert Co-Pay BENefit™ may cover up to $12,000 of your eligible out-of-pocket expenses per year.

Download Enrollment Form »

CSL Behring — A heritage of safety, innovation, and excellence in plasma therapies.

Home Support Services Availability and Reimbursement

Important Safety Information

BERINERT®, C1 Esterase Inhibitor (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients. The safety and efficacy of BERINERT for prophylactic therapy have not been established.

BERINERT is contraindicated in individuals with a history of life-threatening systemic reactions to C1 esterase inhibitor preparations (including anaphylaxis).

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration of BERINERT and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Serious arterial and venous thromboembolic (TE) events have been reported following administration of recommended doses of C1 Esterase Inhibitor (Human) products to patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device; prior history of thrombosis; underlying atherosclerosis; use of oral contraceptives or certain androgens; morbid obesity; and immobility. Weigh benefits/risks before administering to patients with known risk factors for TE events and closely monitor such patients during and after BERINERT administration. TE events also have been reported with C1 Esterase Inhibitor (Human) products when used for unapproved indications at higher than recommended doses.

Appropriately trained patients may self-administer BERINERT upon recognition of an HAE attack. Advise patients to seek medical attention immediately following selfadministration for laryngeal attacks, and to seek medical attention if progress of any attack makes them unable to properly prepare or administer dose of BERINERT.

BERINERT is derived from human plasma. The risk of transmission of infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

The most serious adverse reaction reported in subjects who received BERINERT in clinical studies was an increase in severity of pain associated with HAE. Dysgeusia was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.

BERINERT has not been evaluated in pregnant women or nursing mothers, and should be used only if clearly needed. In clinical trials, the half-life of BERINERT was shorter and clearance was faster in children than in adults; the clinical implication of this difference is not known.

Please see full prescribing information for BERINERT, including the patient product information.

CSL Behring
© 2018 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059d 10/2015